Here is the conf call transcript from

New Post Public Reply Private Reply Replies (0) Message Board
tc2000chartreader
411
Here is the conf call transcript from 2/26/19.
https://storage.googleapis.com/wzukusers/user...262019.pdf

Operator: We'll take our next question from Steve Frazier. Please go ahead.
Steve Frazier: Hey Joe, how are you?
Joseph Moscato: How are you, Steve?
Steve Frazier: I'm doing fine, sir. Hey, first off, let me just say thank you to the prior caller
for his service. I mean, without his service, we wouldn't have this opportunity
to be able to invest in a company like Generex. I do thank him for his service
there.
A question for you on the NuGenerex Immuno-Oncology dividends that we
just did. That you just did. I know you said 60 to 90 days, they're going to
hopefully be going public with that, and possibly through a merger.
As far as the current shares, the current holdings that we will have, is there
any way –? Is that going to show up anywhere on a brokerage? Or, is that just
a book entry form that's going to be held at Generex right now until it is a
publicly traded entity?
Joseph Moscato: All shareholders that are entitled to the dividend should be getting notices
from Broadridge. They will be held in book entry at Broadridge.
Shareholders will have an opportunity, if they want to get a certificate.
They will be able to get one. Or, they can leave it in a book entry. As soon as
we're able to get NuGenerex Immuno-Oncology public, you guys will all be
public day one, so with us.
Steve Frazier: Okay. I guess I was just making sure everybody knows. I was just making
sure everyone knows they're not going to see it in their brokerage accounts.
Anybody looking to see those shares in their brokerage accounts are not
going to actually see them there.
It's just the book entry item that they're entitled to right now. Then, it will
show up eventually when you go public.
Generex_IR_Call_2262019
Page 20 of 35
Joseph Moscato: Yeah, I mean, it's not only they will be entitled to them. They will be entitled
to the public shares. Right now, they are entitled to the private shares. Those
shares, you can request a certificate from Broadridge in the private company.
Steve Frazier: Yeah. I know. I understand that. I just know, they're not going to see it in
their brokerage accounts. They just want people to know that. As far as the
public company.
The company that you're looking to possibly do a merger with, are they a
publicly traded company now? Or, is it something that you guys would merge
with them and go public as a joint entity?
Joseph Moscato: They're a private company. They're deep in the management team. They have
some great synergies with our platforms. They have a bunch of platforms that
are unique and are in the real hot areas cancer research and immunotherapy.
We've been in discussions with them for a long time.
We're hopeful that we can consummate a deal with them, If not, NuGenerex
Immuno-Oncology is deep in its own platforms. We do have our
partnerships. We're looking to add other partnerships and IP.
Either way, we will be taking NuGenerex Immuno-Oncology public in the
coming month to a few months.
We're excited about where we're going with
it.
Steve Frazier: Okay, yeah. I just wanted to find out if that other company was public or
private. It sounds like they're private right now, which is fine. Now, who is
Who received the NGIO shares?
I know it was going to be the existing shareholders that had the 26 million
shares that were out there. The 34 million shares that were being held in
pooled money were not getting the dividends. But, somewhere along the line,
I also heard that maybe the Veneto shares, the shares that were given to
Veneto to purchase them might also be entitled to the NGIO shares.
Were any of the other pooled shares entitled to it? Or, is it only those shares
that were getting the NGIO dividend?

Joseph Moscato: Whatever shares that we have…. Let me back up. As of today, we have made
pledges for stock in varying deals. Let's go back as far as when we acquired
HDS Hema Diagnostics, which is now NuGenerex Diagnostics.
Steve Frazier: Right.
Joseph Moscato: We paid 230,000 share back then to acquire that business. Now, that business
was owned by Steve Berman. Mr. Berman, he was a lot of those shares. He
has never picked those shares up yet from the transfer agent. I don't know.
Generex_IR_Call_2262019
Page 21 of 35
I don't know of anybody since I've taken over this company as CEO that
actually has been physically delivered one share of stock. Now, I have
pledged stock in deals. Let's go specific to the Veneto partners. Those
partners, we did a deal with for $15 million at $2.50 a share.
That comes out of the out of the pool. That pool is already factored into the
market. There are 60 million shares out in total for Generex. Our stock price
reflects the whole 60 billion today. They are receiving a little bit more than
six million shares.
I don't have the exact number. But, let's call it approximately six million
shares of stock. They haven't received that yet. They will receive it, but they
haven't received it. Yes.
Because they did the deal prior to the announcement of the dividend, they are
entitled for four for one. Six million, so break it into a quarter, it would be
about a 1.2 million. I guess.
Steve Frazier: A million.
Joseph Moscato: A 1.2 million or 1.3 million that they're entitled to?
Unidentified Male: It's 1.5, yeah.
Joseph Moscato: Okay. Yes. They are entitled to it. They will receive it

Steve Frazier: Okay,
Joseph Moscato: – Just like anyone else would that was pledged shares or was in
Generex_IR_Call_2262019
Page 22 of 35
entitled to it. Right?
Steve Frazier: Right, they wouldn't. But, is Generex themselves going to have those shares
internally. Or, are they just not going to be dividend out? In other words, if
you were dividending out, again, if you had 60 million shares.
Joseph Moscato: I'm not…. Steve, it's very simple.
Steve Frazier: Yeah.
Joseph Moscato: If you are not part of that date, on the record date, how can I dividend
someone's shares? I can't.
Steve Frazier: Okay. Or, I guess I'm not saying it clearly. If there are 60 million shares total,
okay. If 15 million shares of NGIO would be dividend, if it was on the full 60
million. Since they're not all out there, is Generex – are they doing the whole
15 million and keeping some of the shares themselves just for future?

It adds value to us for the shares of our GMBT that we own? That will add
value. Are there 15 million shares that were dividended out yesterday? But
held, some of them held by you guys?

Joseph Moscato: I don't. But hold by who? I'm not understanding.
Steve Frazier: By Generex, okay. Again, if there are 60 million shares….
Joseph Moscato: Yeah. Let's back up. All of the shares that NuGenerex Immuno-Oncology has
are Generex owned, all of them.

Steve Frazier: Right.
Joseph Moscato: I'm not going to dividend myself. I don't understand your question.
Steve Frazier: That's what I'm asking. You wouldn't? There won't be 15 million shares that
were dividend yesterday. It's going to be some number less than that.
Whatever it was between us and the Veneto?

Joseph Moscato: The Generex owns all the NuGenerex Immuno-Oncology shares. Let's call it.
Let's just say 100 million shares. Generex owns them all. There's no dividend
to Generex. We own all of the shares. We own 100 percent of the Company.

Steve Frazier: Correct –
Joseph Moscato: Alright.
Steve Frazier: – Except for this shares that you just dividend out to shareholders like me.
Joseph Moscato: Yes. That which will be less than – I believe it's less than 6%
.
Generex_IR_Call_2262019
Page 23 of 35
Steve Frazier: Is it all going to be about less than 6% of the overall NGIO? Okay. Alright
Joseph Moscato: _____ [01:05:54].
Steve Frazier: I guess. Yeah. I was belaboring on this question there. I was just trying to get
the…. Yeah.
Joseph Moscato: If there is 100 million shares. Let's call it 100 million shares, or 200 million
shares. Whatever the actual number is. Because we still are structuring that.
Generex will own all of it All of those shares will sit on Generex's balance
sheet. If we have a $5.00 stock price when we go public, all of those shares'
value will be owned by Generex.

Steve Frazier: No. I think that's a total –
Joseph Moscato: That will be huge asset.
Steve Frazier: No. I totally understand that.
Joseph Moscato: That will be…. Okay.
Steve Frazier: That's whatever capital structure you end up putting together when you
finally decide to go public. I meant currently, there's 60 million Generex
shares outstanding.
Sixty million is what is out there. If there are 60 million out there, and you
did a one for every four, you issued basically 15 million, or less than 15
million shares yesterday.
Yeah. Regardless of what they ultimately end up being; and you might have
more than that later on because you're going to obviously bring in capital
partners and whatever else. You're merging into this other company.
They're going to give shares because they've got proprietary platforms that
were either buying or again, merging into. But, then it will have some value
that they're bringing to the table. That my 6% of the shares or whatever that
the shareholders will have, it will get some additional value from their shares.
I'm just saying you haven't really come up with a capital structure yet for
there to be 100 million or 200 million shares. As of yesterday for your book
entry item, there was really only say, 15 million shares generated yesterday
with the one per four dividend. Am I not being clear on that?
J oseph Moscato: The only ones that will get dividend shares are from the pool that we have.
Out of the 34 approximate million pool shares, the only one that will be
receiving any of the dividend since we pledged the pool or sold the pool will
Generex_IR_Call_2262019
Page 24 of 35
be the Veneto deal. Because we consummated that deal.

Steve Frazier: Okay.
Joseph Moscato: We contracted it.
Steve Frazier: What you said is about six million Generex shares. That's about a 1.5 NGIO
dividend yesterday. With the 26 million out to other shareholders, that's 6.5
million. Yesterday, you basically dividended out about eight million shares of
NGIO as a dividend as of yesterday.

Forget the 100 million, or 200 million, or whatever number of shares the
capital structure will be when you finally go public. What you dividended
yesterday for book entry items is about eight million shares, give or take.

Joseph Moscato: Okay.
Steve Frazier: Does that make sense? I was just asking. I guess. Yeah. I don't want to put
you down to a tight spot there. I just was curious.
Joseph Moscato: I mean, I can get you the exact numbers once we finish everything. We'll
probably post that all once it's all finished. But, we have a ways to go before
we know exactly what where we're going to end up.
Steve Frazier: Okay. Yeah.
Joseph Moscato: We don't even know for sure, if we're acquiring and what we're acquiring yet.
All we know is we're in deep discussion to acquire.
Steve Frazier: Okay. No. I understand. Hey, what about what's going on now with –? I
know. I totally understand your Alpha description you did, which was
wonderful. I mean, you just laid it out. I never knew any of that story as far as
how it got delayed multiple times because of what they did.
You did a great job just explaining that, which answered a lot of questions on
Alpha. But now, we have the new funding going on, two million and the
750,000 new funding you just did. I know you have a lot of obligations out
there that were milestone payments.
You mentioned part of these transactions and commitments like the Olaregen.
Don't we owe them $13 million by February 28th, which is in two days? I
mean, $3 million by February 28th, which is in two days? Or, I mean, how do
we come up with the cash for those commitments? Or, is that going to be in
stock? Or, is that being re-negotiated somehow?
Joseph Moscato: As I just said in the introduction, we paid Olaregen about $1.4 million. We
paid Regentys a little over $1 million so far.
Generex_IR_Call_2262019
Page 25 of 35
All of the money that we've been taking in has gone to ourselves and our
obligatory payments as they need money to further their commercialization
efforts as well as their clinical efforts. We will do whatever we have to do to
get them the money necessary to move their platforms forward as we've been
doing.
Steve Frazier: Okay. They're all being lenient is what I'm saying. There's no set time, date
that they have to have the money in? You're giving it to them as they need it?
Joseph Moscato: We give it to them as we need it. We're working hard to get them the money
as they need it so they can make their payments. I'm a big believer in
whatever you pay for, you get big value out of it, right. Everything we've
done is being valued. Let's just take a look at December 4th, alright.
I don't hear this too often. But, we took $14 million off the balance sheet of
hard debt, $14 million we retired completely, which we would have had to
pay; which is now completely gone.
Now, what did that cost us? It cost us a warrant document for 15 million
shares of Generex stock at $2.50 cents exercisable within one year.
That debt, that was wiped out to some – on the debt holder. They have got to
still give me $37 million before they make a dime. But, they forgave $14
million. There are tradeoffs in everything you do, right.
Now, if I'm commercializing a product last year; last year, there were only 18
FDA-approved drugs that were approved by FDA, approximately. Not many
companies get the opportunity to commercialize their own product.
That is huge. You're looking at a $40 billion industry in wounds alone. If we
can capture 2%, and 3%, the cost of money for me is quite reasonable. What
we're doing, quite reasonable.
Steve Frazier: Okay. I understand that. But, we're going to need more of it. I guess. I guess
we're going to see a little bit…. We're going to probably see a few more deals
coming through to help finance things?
Joseph Moscato: Listen, if I'm buying – and let's just call the hospital. If I'm buying by a
hospital network, 60% of it. I need $5 million to get that 60%. But, I'm going
to add over $100 million dollars in revenue with great EBITDA. I would say
that is exponentially worth it, $5 million.
Steve Frazier: No, absolutely. I just meant, if you're going to come up with that. I
understand.
Joseph Moscato: How would I do that? I have to raise the money.
Steve Frazier: Right.
Generex_IR_Call_2262019
Page 26 of 35
Joseph Moscato: Or, I take the debt. The debt would not be quite favorable for our up-lift. But,
that goes against you.
Steve Frazier: I got you. Okay. Again, you're doing a great job. I mean, everything you're
coming across, and everything. Sometimes we just need to ask a few
questions. I love how you answered them.
You don't back away from any question, which is great. You're doing these
monthly, so far monthly – I don't expect you to continue monthly ones. But
,you're doing monthly conference calls, which allows us to ask a lot of
questions that we are….
Even though you put them in 8-Ks, not all of the details are in the 8-Ks. The
details are in there, but the description, the better description that you can
give and your partners they are can give are not in the 8-K.
We do appreciate that. Again, Joe, I appreciate you taking the phone call. I
look forward to seeing what you can do. You keep this going.
Joseph Moscato: Yeah. I mean, listen, I appreciate the call. We love to do the calls. We want to
be as communicative as possible. It's exciting times for Generex and
NuGenerex. For us, the more communicative we are, the better our investors
and shareholders will understand what we're doing.
We're doing a lot of stuff. We have done a lot of stuff in the last six months.
The stuff we've done is unheard of. I don't see many companies executing on
the level that Generex is. We'll continue to do that.
I'm just excited about the next wave of stuff. Because each wave takes a long
time to get together. A lot of lawyers, a lot of finance guys, and a lot of
figuring out, but we have been doing that. We will continue on doing that.
Steve Frazier: Keep it going, and I appreciate it. Thanks, Joe.
Joseph Moscato: Thank you very much. I appreciate it, Steve.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 342

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 297

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 494

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 344

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 562

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 585

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Breast Aesthetics: Embracing Natural Beauty

Updated Category News Views 467

Global Surgeons Advocate for Natural Breast Aesthetics In a groundbreaking initiative, a coalition of prominent plastic surgeons has introduced a new standard for breast augmentation emphasizing 'Natural Breast Beauty'. This initiative, presented at an international symposium in Milan, arose from increasing concerns regarding aesthetically unpleasing results and the...

Continue Reading
Pony AI Receives Strong Buy Ratings from Top Financial Firms

Updated Category News Views 189

Pony AI's Promising Future with Top Ratings Pony AI has recently come into the spotlight after receiving a positive assessment from two major financial institutions, Bank of America and Goldman Sachs. Both firms have initiated coverage on the company, marking it with a favorable ‘buy’ rating. Bank of America has set an ambitious price target of $18, indicating a...

Continue Reading
Rapport Therapeutics: Insights on Neuropsychiatry Conference Participation

Updated Category News Views 116

Rapport Therapeutics at the Neuropsychiatry Summit BOSTON and SAN DIEGO – Rapport Therapeutics, Inc. (NASDAQ: RAPP), a clinical-stage biotechnology company, is making headway in the realm of neurological and psychiatric disorders through its small molecule precision medicines. The company is gearing up to participate in the upcoming TD Cowen's 5th Annual Novel...

Continue Reading
Innovative Credit Card Security Solution by InventHelp Inventor

Updated Category News Views 228

Innovative Credit Card Security Solution An inventor has come up with a groundbreaking idea to guard credit and debit card users against unauthorized transactions. This invention, termed the CREDIT CARD SECURITY LOCK, aims to provide an extra layer of protection, ensuring that only the legitimate cardholder can access their funds. Revolutionizing Payment Security This...

Continue Reading
Polling Insights: Vance and Walz's Debate Performance Analyzed

Updated Category News Views 87

Debate Highlights Between Vance and Walz In a recent debate that captured public attention, Minnesota Governor Tim Walz and Senator J.D. Vance (R-Ohio) engaged in a spirited discussion that left many viewers with strong opinions. According to flash polls conducted by CNN, Vance emerged slightly ahead in the eyes of debate watchers. Polling Results Breakdown The debate was...

Continue Reading